HUTCHMED (CHINA) LIMITED - AMERICAN DEPOSITARY SHA

HUTCHMED Initiates a Phase II/III Trial of Fruquintinib in Combination with Sintilimab for Advanced Renal Cell Carcinoma in China

27 10 2022 06:30:00 提供 Nasdaq GlobeNewswire

HUTCHMED Initiates a Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China

10 10 2022 03:30:00 提供 Nasdaq GlobeNewswire

HUTCHMED Highlights Phase III FRESCO-2 MRCT Data Summary of Fruquintinib in Refractory Metastatic Colorectal Cancer from the Upcoming ESMO 2022 Presentation

07 9 2022 17:30:00 提供 Nasdaq GlobeNewswire

HUTCHMED Highlights Fruquintinib MRCT FRESCO-2 Data to be Presented at the Upcoming ESMO Congress 2022

23 8 2022 03:30:00 提供 Nasdaq GlobeNewswire

Inmagene and HUTCHMED Announce First Participant in Global Phase I Trial of IMG-004

09 8 2022 03:30:00 提供 Nasdaq GlobeNewswire

HUTCHMED and AstraZeneca Announce that TAGRISSO® Plus Savolitinib Demonstrated 49% Objective Response Rate in Lung Cancer Patients with High Levels of MET Overexpression and/or Amplification in SAVANNAH Phase II Trial

08 8 2022 05:01:59 提供 Nasdaq GlobeNewswire

HUTCHMED Announces that Fruquintinib Global Phase III FRESCO-2 Study Has Met Its Primary Endpoint in Metastatic Colorectal Cancer

07 8 2022 19:00:00 提供 Nasdaq GlobeNewswire

HUTCHMED Initiates Phase I Trial of Anti-CD47 Monoclonal Antibody HMPL-A83 in Patients with Advanced Malignant Neoplasms in China

15 7 2022 03:30:00 提供 Nasdaq GlobeNewswire

HUTCHMED Highlights First Presentation of Results of the SAVANNAH Global Phase II Trial of Savolitinib plus TAGRISSO® at the 2022 WCLC Annual Meeting

12 7 2022 19:00:00 提供 Nasdaq GlobeNewswire

Inmagene and HUTCHMED Announce First Participants in Global Phase I Trial of IMG-007

05 7 2022 23:40:34 提供 Nasdaq GlobeNewswire

HUTCHMED to Announce 2022 Half-Year Financial Results

27 6 2022 03:30:00 提供 Nasdaq GlobeNewswire

HUTCHMED Announces TAZVERIK® Approved to be Used in Hainan Pilot Zone in China

01 6 2022 03:33:07 提供 Nasdaq GlobeNewswire

Appointment of Non–Executive Director

16 5 2022 06:00:02 提供 Nasdaq GlobeNewswire

HUTCHMED Receives Complete Response Letter from the U.S. FDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors

02 5 2022 05:00:00 提供 Nasdaq GlobeNewswire

Update on Status under Holding Foreign Companies Accountable Act

30 3 2022 23:00:00 提供 Nasdaq GlobeNewswire

Update on Status under Holding Foreign Companies Accountable Act

11 3 2022 03:00:00 提供 Nasdaq GlobeNewswire

HUTCHMED Receives a US$15 million Milestone from AstraZeneca for Initiating Start-up Activities for a Global Phase III Study of ORPATHYS® in Lung Cancer

06 3 2022 22:30:00 提供 Nasdaq GlobeNewswire

HUTCHMED announces retirement of CEO and appointment of new CEO

03 3 2022 06:30:00 提供 Nasdaq GlobeNewswire

HUTCHMED Reports 2021 Full Year Results and Provides Business Updates

03 3 2022 06:00:01 提供 Nasdaq GlobeNewswire

HUTCHMED Receives Approval to Commercialize ELUNATE® in Macau

01 3 2022 02:30:00 提供 Nasdaq GlobeNewswire